2 years ago

Sitryx Therapeutics Secures $39 Million Series B Funding to Advance Immunometabolism Therapies

  • Sitryx Therapeutics, an Oxford, UK-based biopharmaceutical company focused on regulating cell metabolism to develop disease-modifying therapeutics for chronic autoimmune and inflammatory diseases, raised $39 million in funding

  • New investor Oxford Science Enterprises (OSE) joined existing healthcare investors SV Health Investors, Eli Lilly & Company (Lilly), Sofinnova Partners, Longwood Fund and GSK

  • The company will use the proceeds to progress its immunometabolism-targeting therapies into clinical development.

      • ProblemHealthcare

      "Chronic autoimmune and inflammatory diseases are debilitating, often requiring lifelong treatments with limited efficacy and significant side effects."

      Solution

      "Sitryx Therapeutics is developing disease-modifying therapies that target the metabolism of immune cells, aiming to provide a more effective and safe treatment option for patients with chronic autoimmune and inflammatory diseases."

      Covered on